ロタウイルスワクチンの世界市場規模：タイプ別、エンドユーザー別、地域範囲別、予測

ロタウイルスワクチンの市場規模と予測

ロタウイルスワクチンの市場規模はここ数年良いペースで成長しており、2026年から2032年にかけてCAGR 11.5%で成長すると予測されています。

• ロタウイルスワクチンは、特に新生児や幼児における重篤な下痢や脱水症状の主な原因であるロタウイルス感染と闘うことを目的とした予防措置です。
• ワクチン接種は、免疫系を刺激してロタウイルスに対する抗体を産生させ、ウイルスに対する防御を与え、感染した場合の症状の重症度を低下させる。
• ロタウイルスは非常に感染力が強く、保育園や託児所ではすぐに感染が広がります。予防接種は通常、液体または点滴で経口投与されます。ロタウイルスに関連した入院や死亡の数を世界的に大幅に減少させることができるため、その用途は多岐にわたる。
• さらに、ロタウイルスの予防接種が普及すれば、病気による医療費や生産性の低下に伴う経済的負担を軽減することができます。

ロタウイルスワクチンの世界市場力学

ロタウイルスワクチン市場を形成している主な市場力学は以下の通りです：

主な市場促進要因：

• ロタウイルスワクチンは、特に新生児や幼児における重篤な下痢や脱水症状の主な原因であるロタウイルス感染と闘うことを目的とした予防手段です。
• ワクチン接種は、免疫系を刺激してロタウイルスに対する抗体を産生させ、ウイルスに対する防御を与え、感染した場合の症状の重篤度を低下させる。
• ロタウイルスは非常に感染力が強く、保育園や託児所ではすぐに感染が広がります。予防接種は通常、液体または点滴で経口投与されます。ロタウイルスに関連した入院や死亡の数を世界的に大幅に減少させることができるため、その用途は多岐にわたる。
• さらに、ロタウイルスの予防接種が普及すれば、病気による医療費や生産性の低下に伴う経済的負担を軽減することができます。
• ロタウイルス感染症の世界的負担：ロタウイルスは、世界中の新生児や幼児における重症下痢の主な原因です。ロタウイルス感染症は罹患率が高く、死亡率も高いため、効果的な予防接種プログラムに対する市場の需要が高まっています。
• 政府の取り組みと予防接種プログラム：多くの政府は、国際保健機関とともに、国の予防接種レジメンの一環としてロタウイルスワクチンを積極的に推進しています。このような支援には、資金援助、啓発キャンペーン、公衆衛生プログラムへの組み入れなどが含まれ、ワクチン接種の普及と市場成長を飛躍的に高めることになります。
• ワクチン開発の進歩：継続的な研究開発努力の結果、血清型カバー率と有効性の高い、より新しく効果的なロタウイルスワクチンが発売されています。こうした技術革新はワクチン接種の受け入れと普及を改善し、市場成長を加速します。
• ヘルスケアインフラと意識の向上：世界のヘルスケアインフラ、特に発展途上国のインフラが整備されるにつれて、予防接種サービスはより広く利用できるようになってきています。また、ロタウイルスワクチンの利点に対する一般市民の意識の高まりが市場成長を刺激しています。

主な課題

• コールドチェーン物流と保管：ロタウイルスワクチンは有効性を維持するために継続的な冷蔵が必要であり、コールドチェーンのインフラが限られている地域では大きな問題となります。この制約は、特に低資源環境において、ワクチンへのアクセスを低下させ、廃棄率を上昇させる。
• 高い費用と手頃な価格：ロタウイルスの予防接種は、特に低・中所得国において法外に高価であり、普及を困難にしています。手頃な価格で予防接種を受けられるという制約があるため、国や個人の予防接種プログラムや医療計画に組み込むことができず、市場の拡大が制限されています。
• 他のヘルスケア優先事項との競合：ロタウイルスワクチンは、多くの地域、特にヘルスケア資源が乏しい地域では、他の必須保健対策よりも優先されていないです。このような競合が、ロタウイルスワクチンプログラムの導入や拡大を遅らせ、市場浸透を制限しています。

主な動向

• 新しいワクチン候補の開発：より強力な有効性、より優れた安全性プロファイル、より広範な菌株をカバーする新規ロタウイルスワクチンの開発傾向が顕著です。これらの進歩は、現在のワクチンの限界を解決すると同時に、様々な集団における未充足の要求を満たそうとしています。
• 低・中所得国への注目の高まり：国際保健機関やワクチン製造業者は、ロタウイルス病が最も蔓延している中低所得国でのロタウイルスワクチンへのアクセスを促進することに一層注力しています。価格交渉、現地製造業者との提携、予防接種プログラムへの資金提供などがその取り組みの一つです。
• 国家予防接種プログラムとの統合：ロタウイルスワクチンは、世界各国の予防接種プログラムに組み込まれつつあります。この統合は、ロタウイルスワクチン接種が疾病負担の軽減に有効であるというエビデンスが広がり、各国政府がロタウイルスワクチンを日常的な小児医療に取り入れることを後押ししていることが背景にあります。

目次

第1章 ロタウイルスワクチンの世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 ロタウイルスワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル

第5章 ロタウイルスワクチンの世界市場：タイプ別

• 概要
• ロタリックス
• ロタバック
• ロタテック
• その他

第6章 ロタウイルスワクチンの世界市場：エンドユーザー別

• 概要
• 病院
• 診療所
• 学術・調査
• その他

第7章 ロタウイルスワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 ロタウイルスワクチンの世界市場競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• Merck & Co.
• GlaxoSmithKline plc.
• Beijing Wantai Biological Pharmacy Enterprise Co.
• Walvax Biotechnology Co.
• Bharat Biotech International Limited
• Institute of Vaccines and Medical Biologicals
• Serum Institute of India Pvt. Ltd.
• Chengdu Institute of Biological Products Co
• Incheon Vaccines Ltd
• Deyuan Biotech Group Co.

第10章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Rotavirus Vaccine Market Size And Forecast

The Rotavirus Vaccine Market size is growing at a good pace over the last few years and is expected to grow at a CAGR of 11.5% from 2026 to 2032.

• The rotavirus vaccine is a preventive measure intended to combat rotavirus infection, a leading cause of severe diarrhea and dehydration, particularly in newborns and young children.
• The vaccination stimulates the immune system to develop antibodies against rotavirus, giving protection against the virus and decreasing the severity of symptoms if infected.
• Rotavirus is very contagious and spreads quickly in daycare centers and nurseries. The vaccination is usually given orally, either as a liquid or as oral drops, which makes it convenient for newborns. Its applications are numerous, as it greatly reduces the number of rotavirus-related hospitalizations and fatalities globally.
• Furthermore, widespread rotavirus immunization can reduce the economic burden associated with medical expenses and missed productivity due to illness.

Global Rotavirus Vaccine Market Dynamics

The key market dynamics that are shaping the Rotavirus Vaccine Market include:

Key Market Drivers:

• The rotavirus vaccine is a preventive measure intended to combat rotavirus infection, a leading cause of severe diarrhea and dehydration, particularly in newborns and young children.
• The vaccination stimulates the immune system to develop antibodies against rotavirus, giving protection against the virus and decreasing the severity of symptoms if infected.
• Rotavirus is very contagious and spreads quickly in daycare centers and nurseries. The vaccination is usually given orally, either as a liquid or as oral drops, which makes it convenient for newborns. Its applications are numerous, as it greatly reduces the number of rotavirus-related hospitalizations and fatalities globally.
• Furthermore, widespread rotavirus immunization can reduce the economic burden associated with medical expenses and missed productivity due to illness.
• Global Burden of Rotavirus Infections: Rotavirus is a major cause of severe diarrhea in newborns and young children worldwide. Rotavirus infections have a high incidence rate, as well as significant morbidity and mortality, which drives market demand for effective immunization programs.
• Government Initiatives and Immunization Programs: Many governments, along with international health organizations, are aggressively promoting rotavirus vaccines as part of their national immunization regimens. This support includes funding, awareness campaigns, and inclusion in public health programs, which will dramatically increase vaccination adoption and market growth.
• Advancements in Vaccine Development: Continuous research and development efforts have resulted in the launch of newer, more effective rotavirus vaccines with greater serotype coverage and efficacy. These innovations improve vaccination acceptance and adoption, accelerating market growth.
• Increasing Healthcare Infrastructure and Awareness: Immunization services are becoming more widely accessible as the world's healthcare infrastructure, especially in developing nations, gets better. In addition, increasing public awareness of the benefits of rotavirus vaccine stimulates market growth.

Key Challenges:

• Cold Chain Logistics and Storage: Rotavirus vaccines require continual refrigeration to retain efficacy, which presents a substantial issue in areas with limited cold chain infrastructure. This constraint reduces vaccine accessibility and raises waste rates, especially in low-resource settings.
• High Costs and Affordability: Rotavirus vaccinations are prohibitively expensive, particularly in low- and middle-income countries, making widespread adoption challenging. Affordability constraints limit governments' and individuals' abilities to include these vaccinations in national immunization programs or personal healthcare plans, limiting market expansion.
• Competition with Other Healthcare Priorities: The Rotavirus vaccine is not prioritized over other essential health measures in many locations, particularly in areas with little healthcare resources. This competition for resources and attention slows the introduction and expansion of rotavirus vaccine programs, limiting market penetration.

Key Trends:

• Development of New Vaccine Candidates: There is a significant trend toward the development of novel rotavirus vaccines with stronger efficacy, better safety profiles, and broader strain coverage. These advancements attempt to solve current vaccine limitations while also meeting unmet requirements in a variety of populations.
• Growing Focus on Low- and Middle-Income Countries: International health organizations and vaccine producers are focusing more on boosting access to rotavirus vaccines in low- and middle-income countries, where rotavirus disease is most prevalent. Price negotiations, local manufacturing partnerships, and immunization program funding are among the efforts being made.
• Integration with National Immunization Programs: Rotavirus vaccine is increasingly being integrated into national immunization programs around the world. This integration is aided by expanding evidence of the vaccination's effectiveness in reducing disease burden, which encourages governments to incorporate the vaccine into routine pediatric care.

Global Rotavirus Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the Rotavirus Vaccine Market:

North America:

• According to VMR Analyst, North America is estimated to dominate the Rotavirus Vaccine Market during the forecast period. North America, particularly the United States, has a well-established healthcare infrastructure. This allows for widespread vaccine distribution and delivery, ensuring high immunization coverage and boosting market growth in this region.
• Rotavirus vaccine is actively supported by government health agencies in North America, which provide advice, financing, and inclusion in national immunization programs. These measures increase vaccine adoption, which contributes greatly to market domination.
• North Americans benefit from high levels of health awareness and education, which increases acceptance and demand for immunizations such as the rotavirus vaccine. Public health campaigns increase awareness and adoption.
• Furthermore, North America is home to numerous significant vaccine producers and research organizations that specialize in the development and production of rotavirus vaccines. The region's ability to innovate and produce underpins its dominant position in the global market.

Europe:

• European countries have well-established, comprehensive immunization regimens that include rotavirus vaccines as part of the baby vaccination schedule. This government funding assures high immunization coverage and promotes regional market growth.
• Europe has a high level of healthcare investment, which includes public health measures focused on the prevention of infectious diseases. The investment in healthcare infrastructure and preventive measures contributes to the widespread use of rotavirus vaccines.
• European governments commonly work with international health organizations on vaccine procurement and distribution techniques, which aids in overcoming affordability and accessibility issues. These collaborations help to expand the implementation of immunization programs.
• Furthermore, there is a great emphasis on public health education and awareness in Europe, which has resulted in higher vaccine acceptance rates among the general people. Educational efforts promoting the benefits of rotavirus vaccination boost demand and drive market expansion in the region.

Asia Pacific:

• The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. Asia Pacific has a high incidence of rotavirus infections, necessitating an urgent need for effective vaccinations. The high incidence of rotavirus-related illness and mortality among children in this region emphasizes the crucial need for extensive immunization campaigns.
• Many countries in the Asia Pacific region are rapidly improving their healthcare infrastructure, increasing access to vaccines. Increased healthcare investments and immunization program expansion make it easier to distribute and administer rotavirus vaccines, hence driving market growth.
• Rotavirus vaccination is becoming increasingly important in national immunization programs across the Asia Pacific. These programs, which are frequently funded by international health organizations, increase vaccine uptake and promote significant market growth.
• Furthermore, Populations throughout the Asia Pacific are becoming more aware of the value of vaccination in preventing infectious diseases such as rotavirus. This greater awareness, combined with educational initiatives, drives demand for rotavirus vaccines, resulting in market growth.

Global Rotavirus Vaccine Market: Segmentation Analysis

The Global Rotavirus Vaccine Market is segmented based on Type, End-User, And Geography.

Rotavirus Vaccine Market, By Type

• Rotarix
• Rotavac
• RotaTeq
• Others

Based on Type, the market is segmented into Rotarix, Rotavac, RotaTeq, and Others. The RotaTeq segment is estimated to dominate the Rotavirus Vaccine Market due to its widespread acceptance and use in many countries, its efficacy in avoiding rotavirus gastroenteritis caused by the most frequent strains, and its inclusion in national immunization programs. Furthermore, its pentavalent formulation, which covers five rotavirus strains, provides broad protection, leading to its widespread use. Comprehensive safety and efficacy evidence, lengthy clinical trials, and recommendations from health authorities around the world all help to strengthen the vaccine's adoption.

Rotavirus Vaccine Market, By End-User

• Hospitals
• Clinics
• Academics and Research Institutions
• Others

Based on End-User, the market is segmented into Hospitals, Clinics, Academics and Research Institutions, and Others. The hospitals segment is estimated to hold the majority share in the forecast period of the Rotavirus Vaccine Market. Hospitals are primary healthcare venues where immunizations are provided, particularly to infants and young children, who receive the majority of rotavirus vaccines. The centralized nature of hospital facilities facilitates vaccine distribution and delivery, allowing a large number of people to be vaccinated in a controlled and medically monitored environment. Furthermore, hospitals frequently act as crucial centers of education for new parents about the need for vaccination, providing them with the information and resources they need to protect their children from rotavirus infection.

Key Players

• The "Rotavirus Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck & Co., GlaxoSmithKline plc, Walvax Biotechnology Co., Bharat Biotech International Limited, Institute of Vaccines and Medical Biologicals, Serum Institute of India Pvt. Ltd., Chengdu Institute of Biological Products Co., Beijing Wantai Biological Pharmacy Enterprise Co., Incheon Vaccines Ltd, Deyuan Biotech Group Co., Sanyou Biopharmaceuticals Co., Jilin Akeso Biopharmaceutical Co., CanSino Biologics Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi Pasteur and Pfizer Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Rotavirus Vaccine Market Recent Developments
• In November 2023, Medical Xpress reported a study finding that infants exposed to certain biologics during pregnancy can safely receive a rotavirus vaccine.
• In January 2020, The Press Trust of India reported that the Serum Institute launched a new rotavirus vaccine in India, aiming to be a super-cheap option to combat childhood diarrhea.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ROTAVIRUS VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ROTAVIRUS VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model

5 GLOBAL ROTAVIRUS VACCINE MARKET, BY TYPE

• 5.1 Overview
• 5.2 Rotarix
• 5.3 Rotavac
• 5.4 RotaTeq
• 5.5 Others

6 GLOBAL ROTAVIRUS VACCINE MARKET, BY END-USER

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Academic and Research
• 6.5 Others

7 GLOBAL ROTAVIRUS VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL ROTAVIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Merck & Co.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 GlaxoSmithKline plc.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Beijing Wantai Biological Pharmacy Enterprise Co.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Walvax Biotechnology Co.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Bharat Biotech International Limited
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Institute of Vaccines and Medical Biologicals
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Serum Institute of India Pvt. Ltd.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Chengdu Institute of Biological Products Co
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Incheon Vaccines Ltd
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Deyuan Biotech Group Co.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 APPENDIX

• 11.1 Related Research